Manuel Valiente

Manuel Valiente

Manuel Valiente
Position

Group Leader. EMBO YIP. ERC investigator. Co-founder and Scientific Director of RENACER. Brain Metastasis Group. Molecular Oncology Programme, CNIO.

Reaction to design of new drug to treat glioblastoma that does not respond to chemotherapy

Glioblastoma is an aggressive type of cancer that arises in the brain or spinal cord. Researchers have identified a new drug that exploits DNA repair defects to selectively target tumours that are resistant to chemotherapy treatment with temozolomide. The research is published in Science.